Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Nov 19, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 22,500 | $0.56 | 55,500 |
Nov 19, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 22,500 | -- | 177,500 |
Aug 23, 2018 |
Ten Percent Owner
Trans History: 18
|
Ten Percent Owner | Form 4 | Conversion of derivative security | 22,161 | -- | -- |
Jun 06, 2019 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Jun 06, 2019 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Jun 06, 2019 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Jun 06, 2019 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Jun 06, 2019 |
Director, Ten Percent Owner
Trans History: 14
|
Director, Ten Percent Owner | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Jun 06, 2019 |
Director, Ten Percent Owner
Trans History: 14
|
Director, Ten Percent Owner | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.